Home » Authors » Karen Young

Articles by Karen Young

Hyseq Raises $15M Privately To Develop Proprietary Drugs

April 10, 2002

InterMune Licenses Rights To Phase II Candidate For Fibrosis

April 9, 2002

InterMune Inc. licensed worldwide rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis a drug candidate that plays right into the company’s field of expertise. (BioWorld Today)

Mojave Presents First Human Data From Antigen Delivery System

April 9, 2002

Mojave Presents First Human Data From Antigen Delivery System

April 9, 2002

InterMune Licenses Rights To Phase II Candidate For Fibrosis

April 9, 2002

InterMune Inc. licensed worldwide rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis a drug candidate that plays right into the company’s field of expertise. (BioWorld Today)

Allos Charting Oncology Path, In-Licenses Cancer Product

April 8, 2002

Allos Charting Oncology Path, In-Licenses Cancer Product

April 8, 2002

GenPhar Reveals Platform, Has Partnerships With Army, NIH

April 5, 2002

LifeTime Acquires Cancer Product From Dovetail For Equity Position

April 5, 2002

LifeTime Acquires Cancer Product From Dovetail For Equity Position

April 5, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 8, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
AI drives financings, approvals for APAC med-tech in 2024
BioWorld MedTech
AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific countries played to individual strengths to maximize AI’s applications in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.